SUBSCRIBE
SUBSCRIBE
News   Drug Development

UCB Group Release: New Post-Hoc Analyses Examined Neupro® Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson’s Disease

April 26, 2012 | 
1 min read
ATLANTA--(BUSINESS WIRE)--Insights into the effects of Neupro® (rotigotine transdermal system) on common non-motor symptoms of Parkinson’s disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, LA.
Clinical research Postmarket research
MORE ON THIS TOPIC
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
February 4, 2026
 · 
2 min read
 · 
Heather McKenzie
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.
Obesity
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac